Fig. 2: Immunologic reconstitution of patients treated on the clinical trial.
From: Decrease post-transplant relapse using donor-derived expanded NK-cells
A The median number of absolute lymphocytes (ALC), CD56+, CD3+, CD4+, CD8+, CD19+, CD25+, CD45RO, and CD45RA cells at 30, 90, 180, and 360 days after transplant. Number of all lymphocyte subsets gradually increased and returned to normal by day 90 after transplant. B Number of B and T cell subsets after transplant stratified by NK cell dose level. High number of CD56+ cells was observed in patients who received high NK cell dose (dose level 3: 1 × 108/Kg/dose) compared with low (dose level 1: <1 × 107/Kg/dose) and intermediate dose (dose level 2: 1 × 107–3 × 107/Kg/dose) (P = 0.064). At day 90 and 180, a significantly lower number of CD25+ cells in patients who received higher NK cell dose was observed when compared with low and intermediate dose. The mean number of CD25+ cells at day 90 for patients who received low, intermediate, and high NK dose was 15 cells/mm3 (SD 4.2), 42 cells/mm3 (SD 38) and 6.3 cells/mm3 (SD 5.1), respectively (P = 0.005), and at day 180 were 151 cells/mm3 (SD 108), 66 cells/mm3 (SD 44) and 16 cells/mm3 (SD 14), respectively (P = 0.025). No significant difference in number of CD19+, CD4+, CD8+, and CD3+ cells between patients who received different dose of NK cells. Bars and whiskers represent median ± interquartile range.
